Astellas FY17 Results and FY18e Guidance – No Major Surprise

120 Views04 May 2018 22:39

Astellas Pharma Inc (4503 JP) FY17 results Xtandi (up 17% to ¥295b) and mirabegron (up 28% to ¥126b) ramp-up compensate for lackluster domestic...

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 4-minute read)

Discussions

(Paid Plans Only)

Asia Healthcare Analyst

Pathology Associates Limited

Japan & ChinaHealth CareEquity Bottom-Up

Price Chart(Sign Up to Access)

Insight Stream